ARTICLE | Company News
GlaxoSmithKline, Department of Veterans Affairs endocrine news
October 22, 2007 7:00 AM UTC
The VA removed GSK's Avandia rosiglitazone from its national formulary on Oct. 5 after a review concluded the drug might not afford the same margin of safety as alternative therapies. The oral PPAR ...